2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Supplemental Data Supplemental Data All Versions of this Article: ASN.2008121314v1 20/11/2459    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Ghisdal, L. Articles by Abramowicz, M. PubMed PubMed Citation Articles by Ghisdal, L. Articles by Abramowicz, M. Related Collections Related Article

TCF7L2 Polymorphism Associates with New-Onset Diabetes after Transplantation

Lidia Ghisdal^*, Christophe Baron, Yannick Le Meur, Arnaud Lionet, Jean-Michel Halimi, Jean-Philippe Rerolle, François Glowacki, Yvon Lebranchu, Mireille Drouet, Christian Noël, Hakim El Housni^||, Pascale Cochaux^||, Karl Martin Wissing^*, Daniel Abramowicz^* and Marc Abramowicz^||

*Clinique de Transplantation Rénale and
^||Service de Génétique Médicale, Hôpital Erasme-ULB, Bruxelles, Belgium;
Service de Néphrologie, Centre Hospitalier Universitaire de Tours, Tours, France;
Service de Néphrologie, Centre Hospitalier Universitaire Dupuytren, Limoges, France; and
Service de Néphrologie, Transplantation rénale, Centre Hospitalier Régional Universitaire de Lille, Lille, France

Correspondence: Dr. Lidia Ghisdal, Clinique de Transplantation Rénale, Hôpital Erasme-ULB, 808, route de Lennik, 1070 Bruxelles, Belgique. Phone: +3225553334; Fax: +3225556499; E-mail: lghisdal{at}yahoo.com

Received for publication December 30, 2008. Accepted for publication July 13, 2009.

New-onset diabetes after transplantation (NODAT) is a serious and frequent complication in transplant recipients. Whether NODAT shares the same susceptibility genes as type 2 diabetes is unknown. In this multicenter study, we genotyped 1076 white patients without diabetes at transplantation for 11 polymorphisms that associate with type 2 diabetes. We defined NODAT as a fasting plasma glucose 126 mg/dl on at least two occasions or de novo hypoglycemic therapy. We compared clinical and genetic factors between patients who developed NODAT within 6 mo of transplantation (n = 118; incidence 11%) and patients without diabetes (n = 958). In multivariate analysis, NODAT significantly associated with the following characteristics: TCF7L2 polymorphism (odds ratio [OR] 1.60 per each T allele; P = 0.002), age (OR 1.03 per year; P < 0.001), body mass index at transplantation (OR 1.09 per unit; P < 0.001), tacrolimus use (OR 2.26; P < 0.001), and the occurrence of a corticoid-treated acute rejection episode (OR 2.78; P < 0.001). In summary, our data show that the TCF7L2 rs7903146 polymorphism, a known risk factor for type 2 diabetes in the general population, also associates with NODAT.

Related Article

This Month's Highlights
J. Am. Soc. Nephrol. 2009 20: A12. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673